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Abstract An elevated human T cell lymphotropic virus 1
(HTLV)-1 proviral load (PVL) is the main risk factor for
developing HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP) in HTLV-1 infected subjects, and a
high cerebrospinal fluid (CSF) to peripheral blood mononu-
clear cell (PBMC) PVL ratio may be diagnostic of the condi-
tion. However, the standard method for quantification of
HTLV-1 PVL—real-time PCR—has multiple limitations, in-
cluding increased inter-assay variability in compartments with
low cell numbers, such as CSF. Therefore, in this study, we
evaluated a novel technique for HTVL-1 PVL quantification,
digital droplet PCR (ddPCR). In ddPCR, PCR samples are
partitioned into thousands of nanoliter-sized droplets, ampli-
fied on a thermocycler, and queried for fluorescent signal. Due
to the high number of independent events (droplets), Poisson
algorithms are used to determine absolute copy numbers
independently of a standard curve, which enables highly
precise quantitation. This assay has low intra-assay variability
allowing for reliable PVL measurement in PBMC and CSF
compartments of both asymptomatic carriers (AC) and HAM/
TSP patients. It is also useful for HTLV-1-related clinical
applications, such as longitudinal monitoring of PVL and
identification of viral mutations within the region targeted by
the primers and probe.
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Background
Human T cell lymphotropic virus 1 (HTLV-1), an oncogenic
human retrovirus, is the causative agent of adult-Tcell leukemia
(ATL) and a myelopathy termed HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) (Gessain
and Mahieux 2012). HTLV-1 has also been associated with
other clinical manifestations including uveitis, myositis, and
dermatitis (Gessain and Mahieux 2012). As with all other
human retroviruses, HTLV-1 is transmitted frommother to child
(mainly through breast milk), sexually, or from contact with
infected blood (Kubota et al. 2000). It is currently estimated that
10 to 20 million people worldwide are infected with HTLV-1
(Gessain and Mahieux 2012). The majority of infected individ-
uals will remain lifetime asymptomatic carriers (AC), while up
to 5 % will develop either HAM/TSP or ATL (Proietti et al.
2005). Regions that are highly endemic for HTLV-1 infection
include the Caribbean, Japan, and regions of SouthAmerica and
Africa (Proietti et al. 2005; Gessain and Mahieux 2012).
HTLV-1 predominantly infects T cells (CD4+ and CD8+)
and establishes a reservoir in the memory/effector and
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regulatory CD4+ T cells (Araya et al. 2011; Demontis et al.
2013). Unlike other retroviruses, HTLV-1 replicates mainly
through clonal expansion of the infected cells rather than
through the retroviral life cycle with de novo cell-to-cell
infection. An elevated HTLV-1 proviral load (PVL)—a high
percentage of provirus-carrying cells in the peripheral circu-
lation—is a major risk factor for developing HAM/TSP in
HTLV-1-infected subjects (Furtado Mdos et al. 2012) and is
also found in patients with ATL (Archanjo et al. 2011). The
peripheral blood mononuclear cell (PBMC) PVL is 16-fold
higher in HAM/TSP patients compared to AC, and the risk of
developing HAM/TSP increases exponentially once the
PBMC PVL exceeds 1 % (Nagai et al. 1998). Additionally,
HAM/TSP patients are characterized by an even higher PVL
in the cerebrospinal fluid (CSF) compared to the PBMC
(Demontis et al. 2013). This high PVL is associated with
multiple immunologic abnormalities that contribute to the
development of HAM/TSP. When compared to AC, HAM/
TSP patients have higher levels of spontaneous lymphocyte
proliferation (Sakai et al. 2001; Pinto et al. 2011) increased
HTLV-1 expression, and importantly, a higher frequency of
HTLV-1 specific CD8+ T cells (Kubota et al. 2000; Yamano
et al. 2002), which are thought to be critical mediators of
central nervous system (CNS) injury.
Reliable quantification of HTLV-1 PVL in the PBMC,
serum, CSF, and other tissues is critical for understanding
the clinical associations with this agent and for monitoring
viral infection and evaluating therapeutic interventions in
HTLV-1-infected patients. Importantly, quantification of
CSF PVL in the context of HTLV-1 infection and neurologic
symptoms is of diagnostic utility. For example, HAM/TSP
patients have an elevated CSF to PBMC PVL ratio compared
to HTLV-1-infected subjects with other neurologic disorders,
such as multiple sclerosis (MS) (Nagai et al. 2001b). Real-
time PCR (referred to here as quantitative PCR or qPCR) is
currently the standard method of PVL quantification (Hayden
et al. 2013; Strain et al. 2013). However, this technique has
inherent limitations that may preclude precise and accurate
quantification of viral load (Hayden et al. 2013). Particularly,
the dependence of quantification on extrapolation from a
standard curve often results in high inter-assay variability
and, at times, difficulty in accurately measuring the PVL in
compartments with low numbers of cells, such as the CSF
(Lee et al. 2004). An indirect approach of determining target
DNA quantity via a standard curve is not optimal for viral load
quantification, especially as consistency and reliability are
essential for detecting biologically meaningful thresholds
and changes.
A novel technique, digital droplet PCR (ddPCR), allows
for the direct absolute quantification of a target gene in a given
sample. A restriction enzyme is initially used to fragment the
DNA in each sample. The PCR samples are partitioned into
thousands of nanoliter-sized droplets and then subsequently
amplified on a thermocycler. All droplets are then queried for
fluorescent signal (Pinheiro et al. 2012). Each independent
event (droplet) is defined as either positive or negative for the
target probe by the amplitude of its recorded fluorescence
signal (Hindson et al. 2011). Due to the random, independent
segregation of DNA fragments into droplets, Poisson algo-
rithms can be used to determine absolute copy numbers in the
original sample independently of a standard curve (Pinheiro
et al. 2012).
This direct approach to target gene quantification suggests
that ddPCR may provide a more precise and reliable method
for PVL quantification, particularly when applied to samples
with low numbers of cells. The partitioning of each sample
into thousands of droplets allows for many events to be
queried for fluorescent signal in a single well, thereby increas-
ing the overall precision of quantification per sample
(Pinheiro et al. 2012). Several recent studies have found that
ddPCR successfully quantifies the viral loads of CMV in
plasma and HIV in PBMC (Hayden et al. 2013; Strain et al.
2013). In this study, we examined the reliability of ddPCR in
quantifying HTLV-1 PVL in the PBMC and CSF cells of
HTLV-1-infected individuals.
Results
Characterization of ddPCR for the detection of HTLV-1 tax
Figure 1 displays four representative two-dimensional ddPCR
plots from individuals with varying HTLV-1 positivity in
PBMC DNA. The x-axis displays the amplitude of VIC fluo-
rescence, corresponding to the housekeeping gene RPP30,
while the y-axis displays the amplitude of FAM fluorescence,
corresponding to HTLV-1 tax. For each plot, droplets in the
lower left quadrant are negative for both targets (black),
droplets in the upper left quadrant are positive for HTLV-1
tax only (blue), droplets in the lower right quadrant are pos-
itive for RPP30 only (green), and droplets in the upper right
quadrant are positive for both HTLV-1 tax and RPP30
(brown).
Figure 1a displays the result from representative normal
healthy donor PBMC DNA, containing only the housekeep-
ing gene without amplifiable HTLV-1 tax. Figure 1b–d shows
the plots from PBMCDNA of three representative HAM/TSP
patients with increasing HTLV-1 PVL that range from 3.25 to
19.5 %.
Characterization of ddPCR for HTLV-1 PVL quantification
in PBMC
Following the initial characterization of the assay as shown in
Fig. 1, ddPCR HTLV-1 PVL quantification was extended to
PBMC DNA from 25 HAM/TSP patients, four AC, and 21
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healthy donors (Table 1), (Fig. 2). The PVL was calculated
using the following formula:








The median PBMC PVL for HAM/TSP patients was
13.5 % (range 3–44 %) compared to 2.3 % for AC (range 1–
11 %), which is consistent with previous reports of higher
PVL in HTLV-1 infected individuals with neurologic disease
compared to AC (Nagai et al. 1998). Although the cohort of
AC is small (a known limitation to studying HTLV-1 in non-
endemic areas), the median PBMC PVL was significantly
different between HAM/TSP patients, AC, and healthy donors
(Kruskal-Wallis test, p=5.77×10−09; degrees of freedom=2).
When analyzed in pairs, the PBMC PVL differences between
these patient populations and healthy donors were statistically
significant (Mann-Whitney tests, HAM/TSP versus AC p=
0.0093; HAM/TSP versus healthy donors p<0.0001; healthy
donors versus AC p=0.002).
Lower inter-assay variability of ddPCR compared to qPCR
Though the goal of this study was to characterize a new assay
for HTLV-1 PVL quantification, a comparison of ddPCR and
quantitative real-time (qPCR) was performed, as qPCR is the
most commonly used method of measuring HTLV-1 PVL.
PBMC DNA from five HAM/TSP patients was run on two
separate plates by both ddPCR and qPCR to directly compare
the inter-assay variability of these two methods (Fig. 3a). The
PVL of these individuals ranged from 9.4 to 39.8% by ddPCR
and from 5.0 to 28.4 % by qPCR. As the PVL measurements
were higher by ddPCR (p=0.0152, paired t test), the values
were normalized such that the assays could be compared.
Post-normalization, the assays are highly correlated (Pear-
son correlation coefficient, R2=0.97) (Fig. 3b), with similar
performance by ROC analysis (Fig. 3c). Using the normalized
PVL, we found a lower coefficient of variation for ddPCR
compared to qPCR (Fig. 3d), suggesting stronger inter-assay
reliability of ddPCR.
Low intra-assay variability of ddPCR
To further characterize the precision and reliability of ddPCR
for quantification over a wide range of HTLV-1 PVL, the
intra-assay variability was evaluated. HTLV-1 PBMC PVL
of eight infected individuals was measured by ddPCR in sets
of ten replicates on one plate (Fig. 4). Samples were catego-
rized into three subgroups, similar to previous reports
(Demontis et al. 2013): low PVL (<5 %), medium PVL (5–
10 %), and high PVL (>10 %) (representative plots of each
subgroup are shown in Fig. 1b–d). Three individuals with
PVL values less than 5 % were HTLV-1 positive AC, while
the five individuals with medium and high PVL were HAM/

































Fig. 1 Representative two-dimensional ddPCR plots of individuals with
increasing HTLV-PVL. a PBMC DNA from a normal blood donor. b
PBMCDNA from an HTLV-1-infected individual with a PVL of 3.25%.
c PBMC DNA from an HTLV-1-infected individual with a PVL of
8.46 %. d PBMC DNA from an HTLV-1-infected individual with a
PVL of 19.50 %
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low, medium, and high groups were 1.95, 9.77, and 32.35 %,
respectively, with mean coefficients of variation of 13.7, 7.44,
and 3.4 %, respectively. These data suggest that low and
acceptable CV can be achieved at all HTLV-1 PVL ranges,
with the highest precision and reliability observed in the
medium to high PVL ranges (>5 %), which includes the
majority of HAM/TSP patients (Fig. 2).
Elevated PVL in the CSF of HAM/TSP patients
As HTLV-1 is cell-associated, persisting as an integrated
provirus, HTLV-1 PVL quantification is challenging in com-
partments with low numbers of cells, such as CSF. Digital
droplet PCR was used to quantify CSF PVL, which was then
compared to matched PBMC from seven HAM/TSP patients.
As shown in Fig. 5, CSF PVL was greater than matched
PBMC for each patient (approximately 2.8-fold, see Table 2).
The mean CSF PVL, 47.88 %, was significantly greater than
the mean PBMCPVL, 20.71 % (paired t test, p=0.0036). This
finding is in agreement with previous reports of an elevated
CSF PVL to PBMC PVL ratio in HAM/TSP patients (Nagai
et al. 2001b; Demonti et al. 2013).
Longitudinal monitoring of HTLV-1 PVL using ddPCR
Given the precision and reliability of ddPCR for HTLV-1 PVL
quantification, longitudinal PBMC samples from four HAM/
TSP patients were tested to determine PVL variation over
time. For each patient, PBMC samples collected approximate-
ly 1 year apart for 4 years were run in duplicate (Fig. 6). All
patients were slow progressors with stable disability and
HTLV-1 PVL in the medium to high range. Although in all
HAM/TSP patients the HTLV-1 PVL remained relatively
stable over this 4-year time period, we observed several CV
greater than expected for the corresponding PVL (Fig. 4). For
example, patient 14, with a mean PVL of 9.16 %, falls into the
medium PVL range as defined in this paper (5–10 %), and is
therefore expected to have a CVof 7.44 % (Fig. 4). However,
Table 1 Patient demographics
aEDSS Expanded disability status
scale
b IPEC Instituto de Pesquisa
Clinica Evandro Chagas disability
scale
Subject Sex Age Ethnicity Disease duration Disability score
(EDSSa/IPECb)
HAM-1 F 25 Afro-Caribbean 17 years 8/20
HAM-2 F 50 Caucasian 1 year 1.5/14
HAM-3 F 71 Caucasian 6 years 3/7
HAM-4 M 61 African-American 16 years 6/11
HAM-5 F 52 Afro-Caribbean 7 years 6.5/17
HAM-6 F 52 Afro-Caribbean 5 years 6/14
HAM-7 M 74 Afro-Caribbean 22 years 6/12
HAM-8 F 64 Caucasian 3 years 6.5/14
HAM-9 F 44 African-American 10 years 1.5/8
HAM-10 M 52 Afro-Caribbean 19 years 7/21
HAM-11 M 56 Afro-Caribbean 5 months 8/24
HAM-12 M 65 Caucasian 9 years 6/12
HAM-13 F 63 Afro-Caribbean 16 years 6/14
HAM-14 F 61 Afro-Caribbean 9 years 5/13
HAM-15 F 44 Afro-Caribbean 6 years 1.5/1
HAM-16 M 61 African 15 years 6.5/16
HAM-17 F 53 Afro-Caribbean 8 years 7/21
HAM-18 F 61 Hispanic 6 years 8/25
HAM-19 F 36 Afro-Caribbean 16 years 8/24
HAM-20 F 46 Afro-Caribbean 15 years 6/18
HAM-21 M 41 Caucasian 3 years 7.5/24
HAM-22 F 50 Afro-Caribbean 12 years 7/23
HAM-23 F 63 Afro-Caribbean 6 years 1.5/4
HAM-24 F 56 Afro-Caribbean 6 years 3.5/6
HAM-25 M 67 Caucasian 24 years 6.5/12
AC-1 F 65 Afro-Caribbean N/A N/A
AC-2 M 58 Hispanic N/A N/A
AC-3 F 41 Caucasian N/A N/A
AC-4 F 28 Afro-Caribbean N/A N/A
344 J. Neurovirol. (2014) 20:341–351
in this longitudinal analysis, this patient was found to have a
CVof 22.10 %. Similarly, patient 3 has a mean PVL of 12.3 %
and is therefore categorized in the high PVL range, with an
expected CV of 3.4 %. However, this patient was found to
have a CVof 10.17 %.
Detection of HTLV-1 sequence mutations using ddPCR
In addition to serving as a highly reliable tool for quantifying
HTLV-1 PVL, ddPCR was shown to be useful for detecting
mutations in the target gene. As described previously, the
fluorescence amplitude of the positive droplets reflects
primer/probe binding and is specific to each primer/probe
set. In this study, we observed that the fluorescence amplitude
of tax-positive droplets in a singleplex reaction was approxi-
mately 9,000 for all HTLV-1 infected individuals tested
(Fig. 7a, red arrow). However, for one HAM/TSP patient
(patient 16), the amplitude of the tax-positive droplets was
unusually low, between 3,500 and 4,000 (Fig. 7b, red arrow).
When multiple assay runs and DNA extractions confirmed
this unusual droplet profile, the HTLV-1 tax target sequence
from this subject was analyzed. Eight point mutations
(highlighted in red, Fig. 7c) were found within the region
targeted by the ddPCR HTLV-1 tax primers/probe. One of
these mutations was in the probe-binding region, suggesting
that changes in positive fluorescence amplitude may indicate
sequence mutations in this region. This application of ddPCR
has allowed the identification of HTLV-1 mutations in other
regions of the virus, such as the gag gene, as shown for patient
#19 in Fig. 7d–f.
Discussion
HTLV-1 PVL, or the frequency of infected cells in a given
sample, is an important biomarker of disease in the context of
HTLV-1 infection. A high PVL in the PBMC is a risk
factor for developing HAM/TSP in HTLV-1 infected
individuals, although there is significant PVL overlap
between AC and HAM/TSP patients (Nagai et al.
1998; Yamano et al. 2002; Olindo et al. 2005; Waters
et al. 2011; Demontis et al. 2013). A high PVL in
patients with neurologic disease has been suggested to
drive an activated immune response that may play a
role in disease pathogenesis (Ijichi et al. 1993). Moni-
toring of PVL is therefore important, particularly during
the evaluation of interventional therapies.
A commonly used method for PVL quantification is
real-time quantitative PCR (qPCR). This technique ex-
trapolates from standard curves to quantify viral target
and housekeeping genes and is limited by sensitivity
and high inter-assay variability, particularly at the lower
range of target input. Due to these limitations, a third-
generation digital droplet PCR technology that allows
for direct HTLV-1 PVL quantification was developed. In
this study, we compared the precision and reproducibil-
ity of ddPCR to qPCR, demonstrated the utility of
ddPCR for the detection of HTLV-1 in samples with
low cell numbers (such as CSF), and identified a use
for ddPCR for the identification of viral mutations in
HAM/TSP patient samples.
Digital droplet PCR was shown to be a highly precise and
reproducible method of HTLV-1 PVL quantification. The
coefficient of variation was low, less than 10 %, over a wide
range of PVL. This favorably compares, if not exceeds, reli-
ability of qPCR (Demontis et al. 2013; Grassi et al. 2013).
Importantly, the coefficient of variation of ddPCR was lower
than that of qPCR. Such assay characteristics are critical
when quantifying HTLV-1 PVL and may have clinical
consequence, particularly in patients with low PVL or
low input of cellular DNA. While the present study was
not designed to demonstrate superiority of any PCR
methodology, direct comparison of normalized HTLV-1
PVL measurements by ddPCR and qPCR showed a
strong correlation between the two methods, although
ddPCR demonstrated higher HTLV-1 PVL than qPCR.
This may reflect differences in PCR assay platforms,
different regions of HTLV-1 and housekeeping target
gene amplification, and primer/probe design require-














































Fig. 2 Statistically significant differences in HTLV-1 PBMC PVL be-
tween HAM/TSP patients, asymptomatic carriers, and healthy donors.
Mann-Whitney tests were performed to compare differences between
groups in sets of pairs. HAM/TSP PBMC PVL were statistically different
from asymptomatic carrier PBMC PVL, p=0.0093 (**). HAM/TSP
PBMC PVL were also statistically different from healthy donor PBMC
PVL, p<0.0001 (****). Asymptomatic carrier PBMCPVL versus healthy
donor PBMC PVL were also statistically different, p=0.002 (***)
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The results of the present study are consistent with previous
reports that HAM/TSP patients have significantly higher
HTLV-1 PVL than AC or healthy controls in PBMC (Nagai
et al. 1998; Olindo et al. 2005; Demontis et al. 2013), even
though there were low numbers of AC in this report, a com-





Fig. 3 Strong correlation between ddPCR and qPCR for HTLV-1 PBMC
PVL quantitation, though ddPCR has lower inter-assay variability. a
Replicate, non-normalized PBMC PVL values obtained for five HAM/
TSP patients using qPCR and ddPCR were similar, though the values
obtained by ddPCRwere consistently higher. bA strong correlation exists
between the normalized PVL values for ddPCR and qPCR (Pearson
correlation coefficient, R2=0.97). c An ROC analysis of the normalized
PVL values for each method indicates that the assays perform similarly
for HTLV-1 PVL estimation. d Comparison of each method’s normalized











































Low HTLV-1 PVL (<5%)
Medium HTLV-1 PVL(5-10%)
High HTLV-1 PVL (>10%)
Fig. 4 Low intra-assay variability by ddPCR over a wide range of
HTLV-1 PBMC PVL. The intra-assay variability of ddPCR for low,
medium, and high PVL groups was evaluated by running ten replicates
of PBMC DNA from eight patients (three AC and five HAM/TSP). For
the low PVL group (<5%), the mean PVLwas 1.85%with a mean CVof
13.7 %. For the medium PVL group (5–10%), the mean PVLwas 9.77%
with a mean CVof 7.44 %. For the high PVL group (>10 %), the mean
PVL was 32.245 with a mean CVof 3.4 %
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areas. Importantly, the measurement of HTLV-1 PVL in the
CSF of infected individuals with neurologic symptoms has
been shown to be diagnostically useful (Puccioni-Sohler et al.
2007). Elevated levels of HTLV-1 in the CSF compared to
PBMC have been shown to differentiate HAM/TSP from
patients with other neurologic disease and HTLV-1 infection
(Puccioni-Sohler et al. 2007). However, the precise quantifi-
cation of HTLV-1 PVL in compartments with a paucity of
cells such as CSF is challenging when using PCR-based
assays that measure the amount of cellular target based on a
standard curve. By contrast, ddPCR uses Poisson algorithms
to determine absolute copy numbers independently of a stan-
dard curve, which results in lower inter-assay variability
(Pinheiro et al. 2012). In all seven HAM/TSP patients with
matched CSF and PBMC samples, the CSF PVL was shown
to be significantly higher than the PBMC PVL, with an
average 2.8-fold increase of virus in the CSF. Moreover, in
this small cohort of HAM/TSP patients, we observed that the
three patients with earlier and more aggressive disease had the
highest fold increase in the CSF/PBMC ratio (Fig. 5, patients
2, 11, 18; fold increase >3.5). The remaining four patients,
with the lowest fold increase in the CSF/PBMC ratio hadmore
stable, chronic disease (Table 2). If confirmed in larger co-
horts, this observation could be of diagnostic and prognostic
value.
The precision and reliability of our ddPCR assay also
allowed for the evaluation of longitudinal variation of PBMC
PVL in HAM/TSP patients. In four HAM/TSP patients, we
have shown that the PBMCPVL remained relatively stable over
a period of approximately 4 years (Fig. 6). While minor fluctu-
ations in PBMC HTLV-1 PVL were observed over time, the
biological significance of these changes remains unclear, as they
did not correlate with clinical or radiological findings. However,
since ddPCR is a robust method with low intra- and inter-assay
variability, it will be useful for long- and short-term monitoring
of patient PVL during and after clinical intervention.
Though primarily utilized for PVL quantification, we rec-
ognized an additional use of ddPCR for the detection of
mutations in the target gene sequence, as fluorescence ampli-
tude reflects the binding affinity of the primers and probe to
the target DNA. Two HAM/TSP patients were shown to have
differences in the fluorescence amplitude (one for HTLV-1
tax, one for HTLV-1 gag) compared to 25 HAM/TSP patients
with characteristic fluorescence amplitudes for both viral gene
targets (Fig. 7). Sequence analysis of the HTLV-1 tax target
region for HAM/TSP patient 16 demonstrated eight point
mutations (one in the probe-binding region), while the
HTLV-1 gag target region (Fig. 7c) for HAM/TSP patient 19
showed one mutation in the probe-binding region (Fig. 7f).









































































Fig. 5 Elevated CSF to PBMC PVL in HAM/TSP patients demonstrated
by ddPCR. HTLV-1 PVL is elevated in the CSF of seven HAM/TSP
patients relative to matched PBMC, by approximately 2.8-fold. For each
patient, there is a significant difference between PBMC and CSFHTLV-1
PVL (paired t test, p=0.0036)



















10 18 21 7 Slow progression 53 42.25 72.34 1.71 2
17 10 21 7 Initially rapid course
then slow progression
54 14.61 25.84 1.77 6
12 9 12 6 Slow progression 65 18.08 38.28 2.12 16
6 6 13 6.5 Slow progression 54 18.35 45.06 2.46 2
11 1 24 8 Rapid course 57 13.46 48.21 3.58 52
2 2 13 1.5 Rapid course 50 9.06 32.7 3.61 9
18 1 12 6 Rapid course 38 10.8 50.95 4.72 14
a IPEC Instituto de Pesquisa Clinica Evandro Chagas disability scale
bEDSS Expanded disability status score
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any clinical or atypical presentation of HAM/TSP, this finding
highlights a heretofore-unappreciated application of ddPCR
for the detection of viral mutants.
Conclusions
In conclusion, our study demonstrates that ddPCR is a precise,
reliablemethod for HTLV-1 PVL quantification. This technique
can be used to accurately quantify the PVL in PBMC and CSF
samples of HTLV-1 infected individuals. Importantly, it can be
utilized to study the relationship between PVL in a patient’s
CSF and PBMC, monitor PVL fluctuations over time, and
confidently assess the effects of various clinical interventional
therapies on PVL. Interestingly, the fluorescence amplitude of a
given target gene was shown to allow easy identification of
viral mutations in patient samples. We are currently designing
primers and probe sets specific for other regions of the HTLV-1
genome to allow for differentiation between HTLV-1 and
HTLV-2 in a single multiplex reaction.
Methods
Patients
All samples used in this study were collected from subjects
followed at the Neuroimmunology Branch of the National
Institute of Neurologic Disorders and Stroke in Bethesda,
MD under a protocol studying the natural history of HTLV-1
infection (protocol #98N0047). This study included 25 HAM/
TSP patients, 4 HTLV-1AC, and 21 healthy volunteers
(Table 1). Prior to study inclusion, written informed consent
was obtained from each subject in accordance with the Dec-
laration of Helsinki. The study was reviewed and approved by
the National Institutes of Health institutional review board.
Samples
PBMC were isolated from whole blood using Ficoll-Hypaque
(Lonza, Walkersville, MD) centrifugation (1,200 rpm, 30 min,
room temperature). Following isolation, 3×106 cells were
washed with PBS, pelleted, and frozen at −80 °C until use. To
isolate CSF cells, 5–10 mL of CSF were centrifuged
(1,300 rpm, 10 min, 4 °C) immediately after collection by
lumbar puncture. The CSF supernatant was carefully removed,
and the cell pellet was washed in PBS and stored at −80 °C until
use. DNAwas extracted from the PBMC and CSF cell pellets
using DNeasy Blood and Tissue kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. NanoDrop 1000
(Thermo Scientific, Wilmington, DE) was used to measure the
DNA concentration and purity. The extracted DNA was then
used for both ddPCR and qPCR HTLV-1 PVL quantifications.
Primer/probe design
HTLV-1 tax primers and FAM/MGB probe were designed for
ddPCR using NCBI Primer Blast and Primer3Plus (Table 3).
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Fig. 6 HAM/TSP patients’
PBMC PVL are relatively stable
over a period of approximately
4 years. a HAM/TSP patient 15
had a mean PVL of 18.13 %. b
HAM/TSP patient 13 had a mean
PVL of 12.3 %. c HAM/TSP
patient 14 had a mean PVL of
9.16 %. d HAM/TSP patient 3
had a mean PVL of 10.25 %
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These primers amplify a 154-base-pair region of HTLV-1
tax (NCBI Gene ID 1491938). A temperature gradient
experiment was performed to determine the optimal an-
nealing temperature of 59 °C (data not shown). Addi-
tionally, in a duplex PCR, we amplified a cellular house-
keeping gene, ribonuclease P protein subunit P30
(RPP30, NCBI Gene ID 10556) (Hindson et al.), which
was detected with a VIC/MGB probe (Table 3). The final
concentrations in the ddPCR reaction were 900 nM of
each primer and 250 nM of each probe.
For HTLV-1 PVL quantification by qPCR, a different set of
HTLV-1 tax primers and FAM/TAMRA probe were used to
amplify a 79base-pair region of the tax gene (Table 3) (Nagai
et al. 2001a). The qPCR assay included a standard curve for
HTLV-1 tax and a cellular housekeeping gene, beta-actin. The
standard curve for HTLV-1 tax was derived from TARL-2
murine cell line DNA, known to carry the tax gene (pX) at
one copy per cell (1 μg of TARL2 DNA contains 1.65×105
copies of the pX gene) and included five points with a 1:10
serial dilution (40,000, 4,000, 400, 40, and 4 copies). For the
Fig. 7 DdPCR fluorescence profile indicates mutations in viral region
targeted by primers/probe. aA typical one-dimensional droplet profile for
HAM/TSP patients has a positive HTLV-1 tax population at a fluores-
cence amplitude of 9,000 (red arrow). b The HTLV-1 tax-positive drop-
lets for HAM/TSP patient 16 were observed around an amplitude of
3,500 (red arrow). c Sequence alignment revealed that HAM/TSP patient
16 has eight point mutations (indicated in red) in the region of HTLV-1
tax targeted by the ddPCR primers/probe, one in the probe-binding
region. The primer-binding regions are italicized, and the probe-binding
region is underlined. d A typical one-dimensional droplet profile for
HAM/TSP patients has a positive HTLV-1 gag population at a fluores-
cence amplitude of 11,000 (red arrow). e The HTLV-1 gag positive
droplets for HAM/TSP patient 19 were observed around an amplitude
of 4,000 (red arrow). f Sequence alignment revealed that HAM/TSP
patient 19 has one point mutation (indicated in red) in the region targeted
by the gag probe (underlined)
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beta-actin standard curve, we used β-actin Detection Reagents
(Applied Biosystems, Foster City, CA), which included control
human DNA and TaqMan primers and a FAM/TAMRA probe.
The standard curve was derived from five points containing
30300, 3030, 303.3, 30.3, and 10 copies of beta-actin. The final
concentrations in the qPCR reactions were 900 nM of each
primer and 250 nMof the probe for HTLV-1 tax, and 100 nMof
each primer and 66.6 nM of the probe for beta-actin.
Digital droplet PCR (ddPCR)
DNAwas digested with the restriction enzyme BamH1 (New
England Biolabs, Ipswich, MA) for 30 min at 37 °C, diluted
1:5 with PCR-certified water. The digested diluted DNAwas
mixed with the HTLV-1 tax (or gag) and RPP30 primers and
probes and Bio-Rad 2× Supermix, which was then emulsified
with droplet generator oil (Bio-Rad, Hercules, CA) using a
QX-100 droplet generator according to the manufacturer’s
instructions. The droplets were then transferred to a 96-well
reaction plate (Eppendorf, Hauppauge, NY) and heat-sealed
with pierceable sealing foil sheets (Thermo Fisher Scientific,
West Palm Beach, FL). The duplex PCR amplification was
performed in this sealed 96-well plate using a GeneAmp
9700 thermocycler (Applied Biosystems, Grand Island,
NY) with the following cycling parameters: 10 min at
95 °C, 40 cycles consisting of a 30-s denaturation at
94 °C and a 60-s extension at 59 °C, followed by
10 min at 98 °C and a hold at 12 °C.
Following PCR amplification, the 96-well plate was trans-
ferred to a QX100 droplet reader (Bio-Rad, Hercules, CA).
Each well was queried for fluorescence to determine the
quantity of positive events (droplets), and the results were
displayed as dot plots (Fig. 1).
Quantitative PCR (qPCR)
For qPCR, the amplification of HTLV-1 tax and beta-actin
were singleplexed in a 96-well plate. The final volume of each
reaction was 25 μl (10 μl of DNA at a concentration of 10 ng/
μl, 12.5 μl of 2× Universal TaqMan Mastermix (Applied
Biosystems, Foster City, CA) and 2.5 μl of the primers/
probe). Amplification and data acquisition were carried out
in a Viia7 thermocycler (Applied Biosystems, Foster City,
CA). Thermal cycling conditions were as follows: hold at
50 °C for 2 min, a second hold at 95 °C for 10 min, 45 cycles
of 95 °C for 15 s and 60 °C for 1 min, followed by a final hold
at 25 °C for 2 min.
Data analysis and proviral load calculation
For ddPCR analysis, QuantaSoft software version 1.3.2.0 (Bio-
Rad, Hercules, CA) was used to quantify the copies/μl of each
queried target per well. Thresholds were determined manually
for each experiment, according to the negative controls, which
included a no template control and DNA from a healthy vol-
unteer. Droplet positivity was determined by fluorescence in-
tensity; only droplets above a minimum amplitude threshold
were counted as positive. Negative controls were included in
each experiment and resulted in less than two positive droplets.
All samples were run in duplicate, unless otherwise specified,
and the PVL is the average of the two measurements.
For qPCR analysis, Viia7 software version 1.2.1 (Applied
Biosystems, Foster City, CA) was used to quantify HTLV-1
tax and beta-actin. All samples were run in triplicate and the
average quantity was used to calculate the normalized PVL.
For both assays, the PVL was calculated as the percentage
of infected cells using the following formula (Nagai et al.
2001a):









Data normalization was accomplished by applying the log (base
2) transformation, calculating the mean and standard deviation
(SD), and defining the lower (mean-2SD) and upper (mean+
2SD) values of the expected range for each assay type. These
Table 3 Primer/probe sequences
PCR platform Gene name Primer sequences Probe sequence
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values were used to convert the log transformed values to a
percentage of the expected range for each assay type, by
subtracting the lower range value for the assay first then dividing
by the difference of the upper and lower values of the expected
range for the assay. Linear relationship of the post-normalized
values was assessed using Pearson correlation. The “pROC”
function supported in the statistical programming language R
(http://cran.us.r-project.org/) was used per ROC analysis.
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